Format

Send to

Choose Destination
J Hepatol. 2017 Sep 20. pii: S0168-8278(17)32292-4. doi: 10.1016/j.jhep.2017.09.011. [Epub ahead of print]

Reply to: "Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything" and "More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations".

Author information

1
General Medicine Service, Veterans Affairs Puget Sound Health Care System, United States; Health Services Research and Development, Veterans Affairs Puget Sound Health Care System, United States; Division of General Internal Medicine, School of Medicine, University of Washington, United States. Electronic address: lab25@uw.edu.
2
Health Services Research and Development, Veterans Affairs Puget Sound Health Care System, United States.
3
Diagnostic Imaging Service, Veterans Affairs Puget Sound Health Care System, United States; Division of Interventional Radiology, School of Medicine, University of Washington, United States.
4
Health Services Research and Development, Veterans Affairs Puget Sound Health Care System, United States; Gastroenterology Service, Veterans Affairs Puget Sound Health Care System, United States; Division of Gastroenterology, School of Medicine, University of Washington, United States.
PMID:
28939134
DOI:
10.1016/j.jhep.2017.09.011

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center